EUVIMEDEUVIMED entdecken
Übersichtsarbeit

Tolerance-inducing therapies in coeliac disease — mechanisms, progress and future directions

Ludvig M Sollid

Nature Reviews Gastroenterology & Hepatology · 2024-05 · 21 (5) · 335-347

DOI: 10.1038/s41575-024-00895-3 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Nature Reviews Gastroenterology & Hepatology, online erschienen am 09.02.2024. Verfasst von Ludvig M Sollid. Beteiligte Einrichtung: Norwegian Coeliac Disease Research Centre, Institute of Clinical Medicine, University of Oslo, Oslo, Norway. l.m.sollid@medisin.uio.no. Hauptthemen laut MEDLINE: Celiac Disease. Die Arbeit wurde bisher 24-mal zitiert (Crossref) und nennt 130 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Coeliac disease is an autoinflammatory condition caused by immune reactions to cereal gluten proteins. Currently, the only available treatment for the condition is a lifelong avoidance of gluten proteins in the diet. There is an unmet need for alternative therapies. Coeliac disease has a strong association with certain HLA-DQ allotypes (DQ2.5, DQ2.2 and DQ8), and these disease-associated HLA-DQ molecules present deamidated gluten peptides to gluten-specific CD4+ T cells. The gluten-specific CD4+ T cells are the drivers of the immune reactions leading to coeliac disease. Once established, the clonotypes of gluten-specific CD4+ T cells persist for decades, explaining why patients must adhere to a gluten-free diet for life. Given the key pathogenic role of gluten-specific CD4+ T cells, tolerance-inducing therapies that target these T cells are attractive for treatment of the disorder. Lessons learned from coeliac disease might provide clues for treatment of other HLA-associated diseases for which the disease-driving antigens are unknown. Thus, intensive efforts have been and are currently implemented to bring an effective tolerance-inducing therapy for coeliac disease. This Review discusses mechanisms of the various approaches taken, summarizing the progress made, and highlights future directions in this field.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Celiac DiseaseHumansImmune ToleranceGlutensDiet, Gluten-FreeHLA-DQ AntigensCD4-Positive T-Lymphocytes

Substanzen

GlutensHLA-DQ Antigens

Autor:innen und Institutionen

  • Norwegian Coeliac Disease Research Centre, Institute of Clinical Medicine, University of Oslo, Oslo, Norway. l.m.sollid@medisin.uio.no.
  • Department of Immunology, Oslo University Hospital, Oslo, Norway. l.m.sollid@medisin.uio.no.

Zitieren

APA

Sollid, L. M. (2024). Tolerance-inducing therapies in coeliac disease — mechanisms, progress and future directions. Nature Reviews Gastroenterology & Hepatology, 21(5), 335-347. https://doi.org/10.1038/s41575-024-00895-3

Vancouver

Sollid LM. Tolerance-inducing therapies in coeliac disease — mechanisms, progress and future directions. Nature Reviews Gastroenterology & Hepatology. 2024;21(5):335-347. doi:10.1038/s41575-024-00895-3

BibTeX
@article{Sollid2024,
  author = {Sollid, Ludvig M},
  title = {Tolerance-inducing therapies in coeliac disease — mechanisms, progress and future directions},
  journal = {Nature Reviews Gastroenterology & Hepatology},
  year = {2024},
  volume = {21},
  number = {5},
  pages = {335--347},
  doi = {10.1038/s41575-024-00895-3}
}
Kostenlos starten →